North America Cannabidiol (CBD) Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

North America Cannabidiol (CBD) Market Trends and Insights

Expanding Clinical Adoption In Pain And Anxiety Management

The North America cannabidiol (CBD) market is gaining support from a clearer clinical use case in anxiety, sleep disturbance, and related care settings. A 2024 multicenter randomized clinical trial reported that nanodispersible CBD reduced GAD-7 anxiety scores by 7.02 points versus placebo, while also improving sleep quality and depression measures. Clinical development is also continuing in academic settings, with the University of Florida trial on CBD for anxiety and sleep disturbance moving through Phase 2 and targeting primary completion by late 2026^{[1]ClinicalTrials.gov, “Use of CBD in the Treatment of Anxiety,” ClinicalTrials.gov, clinicaltrials.gov}. Federal policy direction also turned more favorable in late 2025 when the White House instructed agencies to prioritize cannabidiol research and widen physician access pathways. This matters for the North America cannabidiol (CBD) market because brands with stronger evidence, cleaner documentation, and more disciplined manufacturing can move closer to physician recommendation instead of depending only on paid consumer outreach. It also changes brand positioning, since clinical readiness now affects reimbursement access, pharmacy acceptance, and the ability to compete in healthcare-linked channels.

Retail Normalization Of Hemp-Derived CBD Products

The North America cannabidiol (CBD) market is also benefiting from a broader shift toward normalized retail access across major digital and mainstream channels. As large retailers and marketplace operators bring CBD into regular assortment logic, shelf access becomes a quality filter instead of a simple distribution win. Charlotte’s Web said its 2025 growth was supported by expanded presence on Walmart.com, Amazon, and Faire, which showed that broad retail integration is now a basic requirement for scale. This shift does not make competition easier, because tighter assortment rules can push weaker products out of the category and give compliant brands more durable visibility. The North America cannabidiol (CBD) market therefore looks more tiered in 2026, with better-tested and better-documented products holding a clearer path to retention in normalized retail environments.

Strong Pull From Pet Wellness And Veterinary Adjacent Use Cases

The North America cannabidiol (CBD) market is seeing a durable demand push from pet care, which remains one of the clearest higher-growth use cases in the category. Pet care is already the fastest-growing end-use segment, and the appeal is tied to premium spending on companion animal health, behavior support, and pain management. Health Canada’s 2025 consultation showed strong veterinary interest, with 90 of 135 submissions focused on veterinary drugs containing CBD, which suggests that the professional channel wants a formal pathway rather than informal use. That shift matters because a formal veterinary route would move part of demand from casual consumer purchase toward clinician-guided product selection and stronger product standards. The North America cannabidiol (CBD) market could therefore see pet-focused brands gain pricing support, better repeat demand, and stronger channel credibility as veterinary use becomes more structured. The same trend also supports specialization, because pet formulas, dosing formats, and safety expectations differ from mainstream adult wellness products.

E-Commerce And Direct-To-Consumer Brand Scaling

The North America cannabidiol (CBD) market continues to gain momentum from e-commerce, which is the fastest-growing distribution channel through 2031. This growth is not only a volume story, because digital leaders also gain tighter control over pricing, product education, subscription retention, and first-party customer data. cbdMD reported direct-to-consumer net sales of USD 3.8 million in Q2 fiscal year 2026, equal to 67% of total revenue, which showed that direct digital sales still carry major weight inside the operating model. The North America cannabidiol (CBD) market also favors brands that can turn first purchases into subscription demand, because repeat-use products reward consistency, convenience, and trusted replenishment cycles. Established operators therefore gain a structural advantage when they combine digital storefronts, marketplace placement, and offline visibility instead of relying on a single sales path. This is especially important in a category where education, reassurance, and proof of quality often drive the second and third purchase more than the first one.

Patchwork State And Federal Compliance Requirements

The North America cannabidiol (CBD) market still faces a serious drag from uneven compliance rules across jurisdictions and channels. Medterra said California Assembly Bill 8 will halt its THC-containing product sales in the state after July 1, 2026, which shows how state-level action can quickly disrupt existing product portfolios^{[2]Medterra, “California Regulatory Update,” Medterra, medterracbd.com}. Canada is moving through a different process, with consultation and streamlining steps that point to a more defined product pathway, but that contrast also highlights how uneven the regional framework remains. Larger operators can absorb reformulation work, compliance review, and slower approval timing more easily than smaller brands can. This means the North America cannabidiol (CBD) market may continue to consolidate, not only because demand is rising, but because the cost of staying compliant keeps increasing.

Price Erosion From Hemp Biomass Oversupply And Private Labeling

The North America cannabidiol (CBD) market also remains exposed to price pressure from earlier oversupply and the steady growth of private-label activity. Even when consumer demand improves, upstream margin recovery can lag because too many suppliers still compete on low-price extract and simple me-too formulations. This matters most for businesses that lack strong formulation identity, clinical support, or brand trust, since those operators are easier to replace in both retail and online channels. The result is a weaker pricing floor for commodity-style products and a wider performance gap between premium brands and undifferentiated sellers. The North America cannabidiol (CBD) market therefore rewards companies that can defend value through certification, channel fit, product quality, and better use-case clarity rather than price-per-milligram alone.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Source: Hemp Remains The Volume Base While Marijuana-Derived CBD Gains Faster Momentum

Hemp accounted for 71.31% of the North America cannabidiol (CBD) market share in 2025, which kept it firmly ahead of marijuana-derived CBD on a revenue basis. This lead reflects the scale advantage built around hemp cultivation, extraction capacity, established supply routes, and wider compatibility with mainstream wellness positioning across the region. In the North America cannabidiol (CBD) industry, hemp also fits more easily into broad retail and e-commerce models because it has already been normalized for a larger set of commercial use cases. That installed base gives hemp-derived products a strong presence across oils, gummies, capsules, topicals, and pharmacy-adjacent formats that need consistency and familiar sourcing. It also means the largest share of the North America cannabidiol (CBD) market still rests on suppliers that can manage agricultural inputs, extraction standards, and quality documentation at scale.

Marijuana-derived CBD is projected to grow at a 17.38% CAGR through 2031, which places it ahead of the overall market pace and shows that demand is broadening beyond the largest source category. Part of that growth comes from adult-use cannabis settings where consumers often prefer fuller cannabinoid profiles and perceive those formulations as more potent or more complete. The White House focus on expanding cannabinoid research also gives more visibility to clinically oriented development pathways, which may support higher-value formulations across both source groups over time^{[3]The White House, “Increasing Medical Marijuana and Cannabidiol Research,” The White House, whitehouse.gov}. The North America cannabidiol (CBD) market therefore has a dual structure by source, with hemp preserving the larger commercial base and marijuana-derived CBD widening the premium growth lane. This balance matters because it keeps scale economics centered in hemp while allowing faster-growth demand pockets to emerge where clinical perception, channel rules, and consumer preference favor differentiated cannabinoid origin.

By End Use: Wellness Anchors Current Demand While Pet Care And Pharmaceuticals Lift Strategic Value

Wellness and personal use held 32.24% of the market in 2025, which made it the largest end-use category in the North America cannabidiol (CBD) market. This segment remains the volume anchor because it connects CBD with sleep support, stress management, exercise recovery, and familiar daily wellness routines. It is also the easiest category for brands to position across multiple formats, which helps explain why gummies, tinctures, capsules, and topical products all feed into this same demand pool. The broad reach of wellness and personal use gives companies a large consumer entry point, but it also creates more direct price competition and faster imitation. For that reason, brands in the North America cannabidiol (CBD) market often use formulation layering, ingredient pairing, and stronger quality signals to stand out within the largest end-use base.

Pet care is projected to grow at a 16.52% CAGR through 2031, which gives it the strongest growth outlook among end-use segments and shows how quickly the use case is becoming mainstream. Health Canada’s consultation process signaled material interest in veterinary CBD pathways, which supports the idea that pet demand is moving closer to formal professional oversight. Pharmaceuticals also carry strategic weight because physician-directed reimbursement pathways can convert part of CBD demand from discretionary spending into budgeted care spending. That shift matters for the North America cannabidiol (CBD) market because clinical channels place more value on documentation, standardization, and formulation discipline than consumer-led channels do. The end-use structure therefore mixes a large and steady wellness base with two value-accretive lanes, one in pet care and one in pharmaceuticals, that can improve pricing quality and channel defensibility.

By Product Form: Gummies Lead Adoption While Topicals Build A Stronger Clinical Case

Gummies and confectionery held a 28.52% share in 2025, which made them the leading product form in the North America cannabidiol (CBD) market. Their position is tied to precise dosing, discreet consumption, broad familiarity, and easier onboarding for consumers who do not want tinctures or inhaled formats. Gummies also support brand extension because companies can combine CBD with adjacent ingredients and create distinct use-case messages around sleep, calm, recovery, or daily balance. This keeps the format commercially attractive even as the field becomes more crowded, since format familiarity lowers the barrier to trial. In the North America cannabidiol (CBD) industry, gummies continue to function as both a customer acquisition format and a premiumization vehicle when brands add functional ingredients and sharper positioning.

Topicals and skin care are projected to grow at a 16.25% CAGR through 2031, which makes them the fastest-growing form and gives them a different role inside the portfolio mix. This growth reflects demand for localized use cases, stronger interest in anti-inflammatory and skincare applications, and better fit with pharmacy-style recommendations. The North America cannabidiol (CBD) market also benefits when topicals are paired with more evidence-backed delivery approaches, because clinically defensible differentiation matters more as healthcare-linked channels expand. Oils and tinctures still retain importance for experienced users who value dose control and flexible use, while capsules and softgels fit better with standardized routines and a more medical presentation. The product form structure therefore shows a clear split, with gummies holding the broadest consumer reach and topicals, capsules, and other format-specific products shaping the next stage of category depth.

By Distribution Channel: Pharmacy-Led Credibility Supports Share While E-Commerce Expands Reach

Hospital and specialty pharmacies accounted for 32.52% of the North America cannabidiol (CBD) market size in 2025, which made them the largest distribution channel in the regional mix. This leadership reflects the value of pharmacist review standards, product documentation, and tighter confidence around compliant, clearly labeled, and consistently manufactured items. The 2026 physician-directed reimbursement pathway strengthens this channel further because it gives more weight to products that meet formal healthcare expectations and can be integrated into supervised care models. In practice, that creates a self-reinforcing quality loop where better-documented brands gain better shelf access, and better shelf access improves trust, repeat use, and healthcare visibility. For the North America cannabidiol (CBD) market, pharmacy strength is therefore not only a channel share story, but also a signal that compliance and clinical credibility are becoming commercial assets.

E-commerce is forecast to grow at an 18.25% CAGR through 2031, which makes it the fastest-growing channel and one of the clearest engines of volume expansion. Digital channels work well for education-heavy products, because companies can explain dosage, use cases, ingredients, and testing detail in more depth than many physical shelves allow. cbdMD’s 2026 results showed how direct digital revenue remains central to operating performance, especially when brands use subscriptions and repeat-order systems to extend customer lifetime value. Retail stores still matter because they remain an important trial point for new buyers, while specialty outlets and practitioner channels serve more selective consumers who want curated products and stronger trust cues. The distribution picture in the North America cannabidiol (CBD) market is therefore not a simple shift from offline to online, but a layered system where pharmacies build trust, e-commerce builds scale, and physical retail supports discovery.

Geography Analysis

The United States accounted for 40.22% of regional revenue in 2025, which kept it at the center of the North America cannabidiol (CBD) market. Its lead is supported by a deeper wellness retail base, broader e-commerce activity, and stronger visibility of branded CBD products across multiple channels. The most important recent change is the opening of a physician-directed reimbursement route for eligible hemp-derived products within approved Medicare-linked care settings. That change matters because it gives compliant suppliers a path into healthcare decision flows instead of leaving the category tied only to consumer self-selection. It also raises the commercial value of evidence, quality assurance, and pharmacy acceptance in the North America cannabidiol (CBD) market.

Mexico is the fastest-growing country segment with a 16.15% CAGR through 2031, which shows that the regional story is no longer limited to the United States and Canada. Its smaller starting base creates more room for acceleration as formal product access improves and compliant cross-border supply options expand. Demand in Mexico is still earlier in its development, but the opportunity is increasingly visible for companies that can navigate import, registration, and product-quality expectations. This makes Mexico an important medium-term growth lever for the North America cannabidiol (CBD) market, especially for brands that already understand regulated product categories. The commercial appeal is stronger for suppliers with disciplined compliance systems, because faster growth alone does not remove the need for product standardization and trust.

Canada remains a structurally important part of the North America cannabidiol (CBD) market because the country combines high cannabis familiarity with an active policy discussion on non-prescription cannabidiol pathways. Health Canada gathered 135 submissions during its consultation process and later summarized broad stakeholder views on how CBD products might fit into a more accessible health product framework. The March 2025 streamlining amendments also showed that regulators are willing to reduce some process burden within the cannabis framework. If a clearer over-the-counter pathway is adopted, Canada could convert existing familiarity into faster uptake of standardized CBD formats sold through more conventional retail and health channels.